% | $
Quotes you view appear here for quick access.

Prana Biotechnology Limited Message Board

  • rt13101310 rt13101310 Jan 31, 2013 10:23 PM Flag

    Life Sciences Report January 31

    "Prana Biotechnology Ltd. (PBT:ASX) is taking on serious neurodegenerative diseases that disrupt the lives of patients and their families. The company has a miniscule $70M market cap, and shares should move dramatically on positive data. Results of phase 2b studies of the company’s orally bio-available PBT2 small molecule for the treatment of Huntington’s disease should be forthcoming in H2/13, and from an Alzheimer’s disease trial by the end of Q4/13. “This represents one of the biggest risk/reward opportunities of 2013,” says Senior Biotechnology Analyst George Zavoico of MLV & Co. “We are awaiting proof of concept and if it pans out, it should position Prana for a major partnership deal.”

    SortNewest  |  Oldest  |  Most Replied Expand all replies
4.39+0.04(+0.92%)Jul 22 3:57 PMEDT